Family Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Family Management’s Portfolio PGNX Stock Details PGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-10,000	Closed	-$86K	–	78
2016 Q4	$86K	Hold	10,000	–	–	0.06%	63
2016 Q3	$63K	Hold	10,000	–	–	0.04%	75
2016 Q2	$42K	Hold	10,000	–	–	0.02%	80
2016 Q1	$44K	Hold	10,000	–	–	0.03%	71
2015 Q4	$61K	Hold	10,000	–	–	0.03%	76
2015 Q3	$57K	Hold	10,000	–	–	0.03%	95
2015 Q2	$75K	Buy	+10,000	New	+$60.5K	0.03%	93
2014 Q3	–	Sell	-13,000	Closed	-$56K	–	101
2014 Q2	$56K	Hold	13,000	–	–	0.03%	82
2014 Q1	$53K	Hold	13,000	–	–	0.03%	75
2013 Q4	$69K	Hold	13,000	–	–	0.04%	68
2013 Q3	$65K	Buy	+13,000	New	+$70.5K	0.04%	62

Other funds holding PGNX

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Family Management's PGNX Position: Q1 2017 in Review

Family Management sold out of Progenics Pharmaceuticals Inc (PGNX) in Q1 2017, closing a stake of 10,000 shares — an estimated $86K sold.

Family Management first reported a position in PGNX in Q3 2013 and held it in 11 quarters. The position peaked at $86K in Q4 2016. 159 funds tracked by Wall St. Rank hold PGNX as of Q1 2017.

Family Management reported no remaining Progenics Pharmaceuticals Inc position as of Q1 2017 after selling out during the quarter.
Family Management sold 10,000 Progenics Pharmaceuticals Inc shares in Q1 2017, an estimated $86K.
Family Management first reported a position in Progenics Pharmaceuticals Inc in Q3 2013 and held it in 11 quarters.
Family Management's Progenics Pharmaceuticals Inc position peaked at $86K in Q4 2016.
159 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q1 2017.

Based on Family Management's 13F filing for Q1 2017, filed 15 May 2017.